Omega-3 Fatty Acids Counter Smoking's Epigenetic Damage to Lungs

Cigarette smoking causes lasting epigenetic damage — particularly hypomethylation at the AHRR gene locus — that persists long after quitting and contributes to chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Meanwhile, polyunsaturated fatty acids (PUFAs) are known to modulate inflammation, and omega-3s have previously been linked to better lung outcomes. This study is the first large-scale investigation to test whether PUFAs interact with smoking-related epigenetics as a mechanism for their lung health benefits.

Using data from 3,857 current and former smokers in the COPDGene cohort, researchers measured plasma PUFA levels via gas-chromatography mass-spectrometry and assessed lung function by spirometry, emphysema and airway wall thickness by CT scan, and DNA methylation (DNAm) using the Illumina EPIC array. Key epigenetic markers included AHRR methylation (cg05575921), two multi-CpG epigenetic smoking scores, and DunedinPACE (epigenetic pace of aging). Mediation analyses quantified how much of each PUFA's effect on lung outcomes was channeled through DNAm changes.

Higher omega-3 levels were consistently associated with better outcomes across all domains: higher FEV1, FVC, and FEV1/FVC; less emphysema (lower LAA950, higher adjusted lung density); less airway wall thickening (lower Pi10); higher AHRR methylation; lower epigenetic smoking scores; and a slower epigenetic pace of aging. The omega-6:omega-3 ratio showed uniformly opposite — detrimental — associations. Individual omega-6 fatty acids presented a nuanced picture: some showed harmful direct effects on lung phenotypes but beneficial effects when acting through epigenetic pathways. For instance, the direct effect of total omega-3s on FEV1 was +0.0201 standard deviations, with an additional AHRR-mediated effect of +0.0049, while the omega-6:3 ratio showed direct and mediated effects of -0.0074 and -0.0014, respectively.

Replication in the Lung Tissue Research Consortium (LTRC) in both blood and lung tissue supported consistent directions of effect, lending biological credibility to the findings. The extension to lung tissue DNAm is particularly valuable, as it suggests the blood-based epigenetic signals reflect processes occurring at the site of disease rather than solely being peripheral markers.

These results carry meaningful implications for precision nutrition. Former smokers remain at elevated respiratory disease risk even after cessation, and there are few modifiable interventions proven to restore lung health at the epigenetic level. Increasing dietary omega-3 intake — or improving the omega-6:omega-3 balance — could represent a tractable strategy to accelerate epigenetic recovery and protect pulmonary function in high-risk individuals. The findings support further investigation through randomized dietary intervention trials.